Back to top
more

IntelGenx Technologies (IGXT)

(Delayed Data from OTC)

$0.17 USD

0.17
8,650

0.00 (0.00%)

Updated Apr 22, 2024 11:20 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for IGXT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

IntelGenx Technologies Corp. [IGXT]

Reports for Purchase

Showing records 1 - 20 ( 32 total )

Company: IntelGenx Technologies Corp.

Industry: Medical - Drugs

Record: 1

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for IGXT

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: IntelGenx Technologies Corp.

Industry: Medical - Drugs

Record: 2

05/19/2020

Company Report

Pages: 7

Termination of Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: IntelGenx Technologies Corp.

Industry: Medical - Drugs

Record: 3

03/30/2020

Company Report

Pages: 7

Rizaport Hit With Another Delay; Lower $0.50PT; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: IntelGenx Technologies Corp.

Industry: Medical - Drugs

Record: 4

11/11/2019

Company Report

Pages: 8

Rizaport PDUFA in 1Q20; Multiple Pipeline Programs Progressing Well; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: IntelGenx Technologies Corp.

Industry: Medical - Drugs

Record: 5

08/12/2019

Company Report

Pages: 7

Rizaport and Tadalafil Programs in Focus; Adjusting PT to $1.00; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: IntelGenx Technologies Corp.

Industry: Medical - Drugs

Record: 6

05/21/2019

Company Report

Pages: 8

Rizaport NDA Resubmission by 3Q19; Collaboration Agreement With Aquestive; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: IntelGenx Technologies Corp.

Industry: Medical - Drugs

Record: 7

03/26/2019

Company Report

Pages: 7

Rizaport PDUFA Date on April 1 Could Be a Big Catalyst; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: IntelGenx Technologies Corp.

Industry: Medical - Drugs

Record: 8

11/09/2018

Company Report

Pages: 7

Moving Closer to Rizaport Launch; Entering the Red- Hot Cannabis Market with Tilray; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: IntelGenx Technologies Corp.

Industry: Medical - Drugs

Record: 9

08/15/2018

Company Report

Pages: 6

Tadalafil Film on Track for 4Q18 Launch; Alzheimer''s Study Results in 2019; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: IntelGenx Technologies Corp.

Industry: Medical - Drugs

Record: 10

05/15/2018

Company Report

Pages: 6

Two Potential U.S. Approvals by YE18; Lower $1.50 PT on Dilution; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: IntelGenx Technologies Corp.

Industry: Medical - Drugs

Record: 11

04/03/2018

Company Report

Pages: 7

Expect Two Major Approvals in 2019; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: IntelGenx Technologies Corp.

Industry: Medical - Drugs

Record: 12

12/06/2017

Company Report

Pages: 6

NDA Delay Likely Temporary; Rizaport Rights Returned to IntelGenx; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: IntelGenx Technologies Corp.

Industry: Medical - Drugs

Record: 13

11/21/2017

Company Report

Pages: 6

Rizaport PDUFA Date in 1H18; Tadalafil on Track to File by Year End; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: IntelGenx Technologies Corp.

Industry: Medical - Drugs

Record: 14

11/02/2017

Daily Note

Pages: 3

Rizaport NDA Resubmitted; On Track for U.S. Approval in 1H18

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: IntelGenx Technologies Corp.

Industry: Medical - Drugs

Record: 15

08/14/2017

Company Report

Pages: 6

Two NDAs to File in 2H17; Montelukast Phase 2 to Start in 4Q17; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 25.00

Research Provided by a Third Party

Company: IntelGenx Technologies Corp.

Industry: Medical - Drugs

Record: 16

05/12/2017

Company Report

Pages: 6

Two NDAs Filings in Mid-2017; Montelukast Advancing Into Phase 2; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: IntelGenx Technologies Corp.

Industry: Medical - Drugs

Record: 17

03/29/2017

Company Report

Pages: 6

Tadalafil on Track for Mid-2017 Filing; Manufacturing Expansion Planned; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: IntelGenx Technologies Corp.

Industry: Medical - Drugs

Record: 18

02/13/2017

Daily Note

Pages: 3

An Opportunistic Agreement With Tetra Bio- Pharma; Focus Remains on Films; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: IntelGenx Technologies Corp.

Industry: Medical - Drugs

Record: 19

11/22/2016

Daily Note

Pages: 3

Lilly Agreement Clears the Legal Path for Tadalafil VersaFilm; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: IntelGenx Technologies Corp.

Industry: Medical - Drugs

Record: 20

11/16/2016

Company Report

Pages: 6

Rizaport Heading Back to the FDA; Montelukast Moves to Phase 2; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party